ArticleFrontiers in oncology2026
Value of serum CEA and CA19-9 dynamic changes and trajectory modeling in prognosis assessment for non-small cell lung cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the value of dynamic changes and trajectory fitting of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in the prognosis of non-small cell lung cancer (NSCLC). Methods: A retrospective analysis was conducted on 244 NSCLC patients treated in our hospital from January 2019 to December 2022. CEA and CA19-9 levels were collected before treatment and at 14 days, 28 days, 3 months, and 6 months post-treatment. Latent class growth models were used to analyze the change trajectories of the CEA and CA19-9 levels. Independent prognostic factors affecting overall survival (OS) in patients with NSCLC were identified using Cox regression analysis. A Nomogram model was developed to predict survival rates, with the classification performance evaluated using calibration curves and the area under the time-dependent ROC curve (AUC). Results: Both CEA and CA19-9 trajectories in NSCLC patients were categorized into two distinct patterns: a continuously decreasing pattern and a decreasing-then-increasing pattern. The Results from the multivariate COX regression and nomogram indicated that advanced age, smoking, advanced TNM stage, squamous cell carcinoma, and decreased CEA or CA19-9 levels before reaching stable state were factors associated with reduced OS in patients with NSCLC. The AUC values of the ROC curves for the 1-, 2-, and 3-year survival rates in the training set were 0.733, 0.863, and 0.840, respectively. The AUC values for the test set were 0.769, 0.726, and 0.760, respectively. Conclusion: Advanced age, smoking history, high TNM stage, squamous cell carcinoma, initial decrease followed by an increase in CEA, and initial decrease followed by an increase in CA19-9 are risk factors for reduced OS in patients with NSCLC. The clinical application of these factors enables the early identification of high-risk patients, facilitating early detection and intervention, and provides valuable data references for improving the prognosis of patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.